老虎证券

Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%

Benzinga
2021-09-28
  • Ziopharm Oncology Inc (NASDAQ:ZIOP) announced a restructuring enabling the Company to advance its TCR program. 
  • The Company will eliminate approximately 60 positions and expects the changes will extend the cash runway into 1H of 2023. Earlier, ZIOP expected cash runway into Q4 of 2022.
  • As of June 30, 2021, the Company had approximately $76.7 million of cash and cash equivalents.
  • The Company also announced that dosing in its TCR-T Library Phase 1/2 trial will start in 1H of 2022 after experiencing unforeseen delays caused by inadequate resources at its contract manufacturer. 
  • The Company is investing in its manufacturing capabilities to accelerate patient dosing. It is committed to operationalizing internal manufacturing capabilities in 1H of 2022 to support the first patient dosing.
  • Price Action: ZIOP stock is down 15.1% at $1.8 during the premarket session on the last check Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10